Dr. Merry Jennifer Markham, MD

Dr. Markham practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Markham's NPI, 1548345994, was assigned on October 26, 2006. Dr. Markham graduated from University of Miami, Miller School of Medicine in 2001. Dr. Markham holds Florida license ME90954.

Dr. Markham's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Markham also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Markham's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dr. Markham is also affiliated with UF Health Shands Hospital. The medical group on file is UF Health Physicians. Dmand AI also links Dr. Markham to 2 more group practices and clinics, 1 breast imaging center, 1 hospital outpatient department and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Markham practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Markham's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Markham is board certified in medical oncology by the American Board of Internal Medicine. Dr. Markham is licensed in Florida.

Dmand AI lists chronic leukemia among the conditions Dr. Markham treats.

CMS data shows 296 Medicare services from Dr. Markham across 8 procedure codes in 2024, for 144 Medicare patients. Medicare paid $21,076 for them.

CMS counts 144 Medicare patients who saw Dr. Markham in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Markham's median patient age at 67, with 94% women.

In 2024, Dr. Markham wrote 152 Medicare Part D claims for 45 patients. 62% of them were for generic drugs. CMS names the drug for 37 of them, across 3 drugs with 11 or more claims each, at $249,900 in total drug cost. In 2023, CMS named 28 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 48 out of 100 for Dr. Markham for performance year 2024, reported through an alternative payment model (APM). Dr. Markham accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Markham as offering telehealth.

Dmand AI links 96 papers to Dr. Markham, published from 2010 to 2025. 2022 was the busiest year, with 13. The most frequent topics are Medical Oncology, Communication and Florida. Dr. Markham has published most often in JCO Oncol Pract. Dr. Markham's most frequent co-authors are Martina Cathryn Murphy, MD, Julia Lee Close, MD and Thomas J. George, MD.

Dmand AI links Dr. Markham to 11 clinical trials, 5 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Ovarian Neoplasms and Fallopian Tube Neoplasms. National Cancer Institute (NCI) sponsors the most, 8. Open Payments lists research payments to Dr. Markham that name 1 trial.

CMS Open Payments shows 3 general payments to Dr. Markham from 2 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 97% of the total. GlaxoSmithKline, LLC. paid the most, $2,175. It also lists 1 research payment totaling $2,316 in 2018, naming 1 clinical trial.

Dmand AI lists 3 awards for Dr. Markham, most recently Fellow in 2020.

Dr. Markham graduated from University of Miami, Miller School of Medicine in 2001. Dr. Markham is a member of ACP, ASCO and Society of Gynecologic Oncology.